Image: Conceivable

Conceivable Life Sciences has secured $18 million in Series A funding to advance its automated IVF lab technology. The round was led by ARTIS Ventures, with participation from Atlantic Health Venture Studio, Muse Capital, and Scrub Capital. The company has now raised over $39 million in total funding.

The funds will support the company’s ongoing commercial pilot program in Mexico City and preparations for a U.S. launch planned for early 2026. The biotech company has developed technology that combines AI and robotics to automate more than 200 steps required in IVF embryo creation. They achieved a significant milestone with the world’s first fully automated intracytoplasmic sperm injection (ICSI), performed both onsite and remotely across 3,000 miles between reproductive cells and the embryologist operator in New York.

“Despite significant clinical advances since the first IVF child was born almost 50 years ago, IVF labs remain largely manual, artisanal, and lacking in the kind of automation and robotics that have transformed other branches of advanced medicine,” said Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Product Officer of Conceivable. “Our world class, interdisciplinary team of experts in embryology, automation, AI, robotics, advanced optics, and machine vision is transforming this outdated model. Even in early testing, our clinical outcomes rival the best IVF labs in the world. As we accelerate our program to expand access, we anticipate even better results, heralding a new chapter in IVF.”

The funding will support a commercial pilot, including an ongoing 100-patient Institutional Review Board (IRB) study. A previous IRB study using their first-generation platform resulted in 22 pregnancies from first embryo transfers.

“Conceivable’s approach to IVF, combining AI and cutting-edge robotics to create an entirely new 21st century model for IVF, will transform the field worldwide, catalyzing a new era of quality, scale, accessibility, and follow-on innovation,” said Stuart Peterson, founder and Managing Partner at ARTIS Ventures. “Even in the U.S., 80% of infertile couples go untreated, unable to access IVF because of high cost, proximity to care, or both. Conceivable is creating a scalable solution that democratizes IVF and delivers equity in fertility care.”

Show CommentsClose Comments

Leave a comment